Intravitreal Pharmacotherapy

On this page

Foundations & Agents - Drug Delivery Drama

  • Intravitreal (IVT) Route:
    • Direct drug delivery to vitreous.
    • Bypasses blood-retinal barrier (BRB).
    • Achieves high local drug concentration.
    • Minimizes systemic side effects.
  • Key Risks:
    • Endophthalmitis
    • Retinal detachment (RD)
    • ↑Intraocular Pressure (IOP)
    • Cataract (with steroids)

Intravitreal injection technique illustration

Common IVT Agents:

Agent ClassMOA HighlightsExamples (Dose)Key UsesMajor Risks
Anti-VEGFBinds VEGF-A; ↓neovasc, ↓permeabilityRanibizumab (0.5 mg), Aflibercept (2 mg), Bevacizumab (1.25 mg), Brolucizumab (6 mg)nAMD, DME, RVO, CNVMEndophthalmitis, inflammation, ↑IOP, RD
CorticosteroidsAnti-inflammatory, ↓permeability, anti-angiogenicTriamcinolone (4 mg), Dexamethasone implant (0.7 mg), Fluocinolone implant (0.19 mg)DME, RVO, Uveitis↑IOP (glaucoma), cataract, endophthalmitis
AntibioticsAnti-bacterialVancomycin, CeftazidimeBacterial endophthalmitisRetinal toxicity (dose), local irritation

Key Indications - Retina's Rescue Remedies

  • Wet AMD (wAMD):
    • Patho: CNV (VEGF-driven).
    • Drugs: Anti-VEGF (Ranibizumab, Aflibercept, Bevacizumab, Brolucizumab).
  • Diabetic Macular Edema (DME):
    • Patho: ↑VEGF, inflammation → ↑permeability.
    • Drugs: Anti-VEGF; Corticosteroids (Dexamethasone, Fluocinolone implants).
  • Retinal Vein Occlusion (RVO) Macular Edema:
    • Patho: Ischemia → ↑VEGF → edema.
    • Drugs: Anti-VEGF; Corticosteroids.
  • Myopic CNV (mCNV):
    • Patho: CNV in pathologic myopia (VEGF).
    • Drugs: Anti-VEGF.
  • Non-infectious Posterior Uveitis:
    • Patho: Inflammation → macular edema/vitritis.
    • Drugs: Corticosteroids.
  • Infectious Endophthalmitis:
    • Patho: Intraocular infection.
    • Drugs: Antibiotics (Vancomycin+Ceftazidime); Antifungals (Amphotericin B, Voriconazole).

⭐ Wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) are the most frequent indications for intravitreal anti-VEGF injections.

The Injection Journey - Precision Pokes

  • Goal: Deliver drug to vitreous, minimize complications.
  • Key Prep:
    • Anesthesia (topical/subconjunctival).
    • Antisepsis: Povidone-iodine 5% or 10% (crucial!).
  • The Poke:
    • Needle: 30G or 32G.
    • Site: 📌 SIT (SuperoTemporal preferred, also InferoTemporal).
    • Distance from limbus: Phakic 3.5-4 mm; Pseudophakic/Aphakic 3-3.5 mm.
    • Angle: Perpendicular to sclera.

Intravitreal injection angles and technique

⭐ Strict aseptic technique, including topical povidone-iodine application, is paramount to minimize the risk of post-injection endophthalmitis.

Risks & Roadblocks - Cautionary Tales

  • Common/Mild (Usually Self-Limiting):

    • Subconjunctival hemorrhage
    • Transient ocular pain, foreign body sensation
    • Floaters (e.g., air bubble)
    • Transient IOP ↑ (monitor if >21 mmHg)
    • Corneal abrasion
  • Serious/Vision-Threatening:

    • Endophthalmitis: Incidence ~0.05% per injection. ⚠️ Most feared!
      • Key signs: 📌 RSVP (Redness, Severe pain, ↓Vision, Pus/hypopyon)
    • Retinal Detachment (RD): Incidence ~0.01-0.7%
    • Vitreous Hemorrhage
    • Lens Damage / Cataract (esp. phakic eyes)
    • Sustained IOP ↑ / Glaucoma
    • Sterile Uveitis / Intraocular Inflammation
    • Systemic (rare): e.g., thromboembolic events (anti-VEGF)

⭐ Post-injection endophthalmitis, though rare (~0.05%), is the most devastating complication, typically presenting with pain, vision loss, and hypopyon within days.

Intravitreal injection procedure

High‑Yield Points - ⚡ Biggest Takeaways

  • Anti-VEGF agents (Ranibizumab, Bevacizumab, Aflibercept) are primary for wet AMD, DME, and RVO.
  • Ranibizumab is an antibody fragment; Bevacizumab is a full antibody (used off-label).
  • Aflibercept is a potent VEGF trap binding VEGF-A, VEGF-B, and PlGF.
  • Intravitreal steroids (Triamcinolone, Dexamethasone implant) treat inflammatory conditions like uveitis, DME, RVO.
  • Key risks: endophthalmitis, retinal detachment, increased IOP (↑IOP), and cataract.
  • Ozurdex (Dexamethasone implant) is biodegradable; Iluvien (Fluocinolone implant) is non-biodegradable.

Practice Questions: Intravitreal Pharmacotherapy

Test your understanding with these related questions

Drug commonly used as immunosuppressive therapy for non-infectious uveitis is -

1 of 5

Flashcards: Intravitreal Pharmacotherapy

1/10

What is the treatment of exudative retinal detachment?_____

TAP TO REVEAL ANSWER

What is the treatment of exudative retinal detachment?_____

Systemic steroids

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial